Lung diseases are the leading cause of mortality in the U.S. Current therapy mainly relies on short-term pharmacotherapy and lung transplantation with limited sustained clinical benefit. Stimulating propagation of alveolar epithelial cells (AECs could increase the lung's capacity to undergo self-repair. Nevertheless, AEC expansion in a diseased lung is frequently handicapped by the lack of epithelially-active cues from the dysfunctional surrounding microenvironmental/niche cells. Consequently, impaired lung repair often provokes excessive scar formation and fibrosis that might inhibit epithelial expansion. We have shown that surgical removal of left lung lobe (pneumonectomy) in mice causes compensatory re-alveolarization in the right lungs. This alveolar regeneration is stimulated by platelets and pulmonary capillary endothelial cells (PCECs). Following pneumonectomy (PNX), platelets deposited in the right lungs upregulate membrane-type metalloproteinase MMP14 in PCECs to stimulate the proliferation of alveolar epithelial stem/progenitor cells such as type 2 AECs (AEC2s). Thus, platelets upregulate epithelially active MMP14 in PCECs to elicit alveolar regeneration. Since this hemo-vascular niche is readily accessible to the circulation, it represents an attractive target to enable therapeutic lung repair. Endothelial MMP14 stimulates AEC expansion by releasing the ectodomain of transmembrane heparin-binding EGF (HB-EGF) that activates EGF receptor (EGFR). Pilot data suggest that MMP14 localized in endothelial cell caveolae blocks lung fibrosis via liberating anti-fibrotic molecule cysteine-rich protein 61 (Cyr61 from extracellular matrix. Caveolar enrichment of MMP14 is induced by platelet-mediated fibroblast growth factor receptor 1 (FGFR1) activation in PCECs. Thus, we hypothesize that MMP14 in the endothelial cell caveolae promotes lung regeneration and blocks fibrosis. To test this hypothesis, we will use mouse pneumonectomy and lung fibrosis model induced by repeated intratracheal injection of Bleomycin to 1) define how endothelial MMP14 processes HB-EGF and Cyr61 to regulate lung regeneration and fibrosis; 2) investigate FGFR1-dependent regulation of MMP14 function. Moreover, we also aim to combine PCEC-targeted gene transduction system and platelet infusion to direct MMP14 in the caveolae of PCECs to promote lung regeneration and prevent fibrosis. This study will help to elucidate how microenvironmental cues such as endothelial MMP14 modulate lung regeneration and fibrosis. Positive outcome of the proposed experiments will help to design a niche-targeted regenerative therapy to facilitate functional lung repair without fibrosis.

Public Health Relevance

Lung diseases such as pulmonary fibrosis are the 4th leading death cause in the U.S.. Current therapy mainly relies on lung transplantation with limited clinical benefit. Expansion of specific stem cells in the injured lung can enhance the lung's capacity to repair itself. However, stem cell expansion is frequently inhibited by the surrounding microenvironmental cells in the diseased lungs. Instead, the lungs form excessive scar that blocks repair and causes loss of respiratory function. Therefore, coaxing the microenvironmental cells to generate beneficial signals that stimulate stem cell proliferation would potentially increase the lung's capacity to successfully regenerate. We have previously shown that in mice after removal of the left lung, blood vessels in the remaining right lungs express a molecule MMP14 to increase stem cell expansion and reduce scar formation, resulting in restoration of lung weight and function. Thus, we will study how blood vessel MMP14 modulates stem cell function and prevent scar formation in mouse models of lung injury. We also plan to selectively induce MMP14 expression in the blood vessel of damaged lungs to reinstate efficient lung regeneration. Our study will help to understand how supporting microenvironmental cells such as blood vessel regulate lung regeneration and scar formation. The outcome of our study can enable therapeutic strategy to regenerate a diseased lung without scar formation.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Lung Injury, Repair, and Remodeling Study Section (LIRR)
Program Officer
Lin, Sara
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Icahn School of Medicine at Mount Sinai
Internal Medicine/Medicine
Schools of Medicine
New York
United States
Zip Code
Cao, Zhongwei; Ye, Tinghong; Sun, Yue et al. (2017) Targeting the vascular and perivascular niches as a regenerative therapy for lung and liver fibrosis. Sci Transl Med 9:
Shido, Koji; Chavez, Deebly; Cao, Zhongwei et al. (2017) Platelets prime hematopoietic and vascular niche to drive angiocrine-mediated liver regeneration. Signal Transduct Target Ther 2:
Cao, Zhongwei; Scandura, Joseph M; Inghirami, Giorgio G et al. (2017) Molecular Checkpoint Decisions Made by Subverted Vascular Niche Transform Indolent Tumor Cells into Chemoresistant Cancer Stem Cells. Cancer Cell 31:110-126
Rafii, Shahin; Ginsberg, Michael; Scandura, Joseph et al. (2016) Transplantation of Endothelial Cells to Mitigate Acute and Chronic Radiation Injury to Vital Organs. Radiat Res 186:196-202
Ding, Bi-Sen; Liu, Catherine H; Sun, Yue et al. (2016) HDL activation of endothelial sphingosine-1-phosphate receptor-1 (S1P1) promotes regeneration and suppresses fibrosis in the liver. JCI Insight 1:e87058